Publication | Closed Access
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
44
Citations
33
References
2019
Year
MedicineLung AdenocarcinomaUncommon Egfr P.l747pPathologyBronchial NeoplasmCancer TreatmentCancer GeneticsP.l747s MutationsOncologyCell BiologyLung CancerCancer Research
| Year | Citations | |
|---|---|---|
Page 1
Page 1